Schrodinger, Viva collaborate on structure-based drug discovery

By The Science Advisory Board staff writers

July 28, 2020 -- Schrodinger and Viva Biotech have entered a strategic collaboration to expand structure-based drug discovery by generating de novo crystal structures of high-value targets.

Under the terms of the collaboration, Schrodinger will identify drug discovery targets for which there are currently no crystal structures. Viva Biotech will use x-ray crystallography design to structurally enable the targets by generating high-resolution structures with bound ligands.

Schrodinger will then use its computational platform to explore chemical space with the goal of designing novel therapeutic candidates for the targets.

Cerevel, Cyclica partner on AI-based drug discovery
Cerevel Therapeutics and Cyclica have announced a research collaboration that will use artificial intelligence (AI) to develop new neurological medicines.
NIH awards Boragen grant for antimalarial drug discovery
Boron-based discovery platform firm Boragen has received a phase I Small Business Innovation Research grant from the U.S. National Institutes of Health...
U.S. DOE launches National Virtual Biotechnology Laboratory

The U.S. Department of Energy (DOE) has launched the National Virtual Biotechnology Laboratory to unite the efforts of its 17 laboratories around the...

Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter